{"doi":"10.1002/lio2.779","title":"Treatment failure patterns are similar between p16− and p16+ oropharyngeal squamous cell carcinomas","abstract":"Abstract Background The incidence of p16+ oropharyngeal squamous cell carcinoma (OPSCC) has been increasing. The notion that p16+ OPSCC has a propensity for atypical and disseminating metastasis has gained traction. We compared treatment failure patterns in p16+ and p16− OPSCC and evaluated survival impact. Methods Retrospective analysis of patients with recurrent/metastatic OPSCC disease between 1/2009 and 12/2019. Results Thirty‐eight p16+ and 36 p16− patients were identified. Three distinct failure patterns (distant vs. locoregional, atypical vs. typical, and disseminating vs. non‐disseminating) were studied. No significant differences were found between p16+ and p16− patients. Multivariate analysis showed p16 status was an independent prognostic biomarker; p16+ patients have a favorable overall survival compared to p16− patients (HR 0.34, 95% CI 0.16–0.77; P = .005). Conclusions We challenge the view that p16+ OPSCC exhibits a distinctive treatment failure pattern and showed that p16 status impacts patient survival independent of disease progression.","journal":"Laryngoscope Investigative Otolaryngology","year":2022,"id":295433,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9543,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":960197,"name":"Richard Müller","orcid":"0000-0002-7441-0964","position":1,"is_corresponding":false},{"id":981373,"name":"Kate Clancy","orcid":"0000-0003-2877-1408","position":2,"is_corresponding":false},{"id":960198,"name":"Brandon Vu","orcid":"0000-0001-8399-7894","position":3,"is_corresponding":false},{"id":427143,"name":"Shanying Gui","orcid":null,"position":4,"is_corresponding":false},{"id":706387,"name":"Jason E. Thuener","orcid":"0000-0002-5035-4611","position":5,"is_corresponding":false},{"id":922465,"name":"Jay Wasman","orcid":"0000-0002-6777-8437","position":6,"is_corresponding":false},{"id":872493,"name":"Shawn Li","orcid":"0000-0001-8841-4694","position":7,"is_corresponding":false},{"id":981374,"name":"Nicole Fowler","orcid":"0000-0002-6484-1453","position":8,"is_corresponding":false},{"id":574679,"name":"Rod Rezaee","orcid":"0000-0002-2978-6153","position":9,"is_corresponding":false},{"id":960199,"name":"Pierre Lavertu","orcid":"0000-0002-1265-105X","position":10,"is_corresponding":false},{"id":427146,"name":"Theodoros N. Teknos","orcid":null,"position":11,"is_corresponding":false},{"id":425789,"name":"Quintin Pan","orcid":"0000-0001-6952-3529","position":12,"is_corresponding":false},{"id":427144,"name":"Wendi Quinn O’Neill","orcid":null,"position":13,"is_corresponding":false},{"id":708705,"name":"Chelsea S. Hamill","orcid":"0000-0003-0523-7608","position":0,"is_corresponding":true}],"reference_count":13,"raw_metadata":null,"created_at":"2026-07-19T00:31:08.861377Z","pmid":"36000056","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}